DiaMedica Therapeutics (DMAC) Cash from Financing Activities (2018 - 2026)

DiaMedica Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $417000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 358.24% year-over-year to $417000.0 in Q1 2026; TTM through Mar 2026 was $44.2 million, a 265.73% increase from a year earlier, with the FY2025 full-year figure at $43.9 million, up 265.82% from the prior year.
• Cash from Financing Activities retreated to $417000.0 in Q1 2026 per DMAC's latest filing, from $12.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $36.8 million in Q2 2023 and bottomed at -$6000.0 in Q3 2023.
• The 5-year median for Cash from Financing Activities is $91000.0 (2025), against an average of $5.5 million.
• Biggest YoY gain for Cash from Financing Activities was 1842600.0% in 2023; the steepest drop was 200.0% in 2023.
• Year by year, Cash from Financing Activities stood at -$1000.0 in 2022, then changed by 0.0% to -$1000.0 in 2023, then jumped by 12100.0% to $120000.0 in 2024, then surged by 9975.83% to $12.1 million in 2025, then tumbled by 96.55% to $417000.0 in 2026.
• Per Business Quant, the three latest DMAC Cash from Financing Activities figures stand at $417000.0 (Q1 2026), $12.1 million (Q4 2025), and $31.5 million (Q3 2025).